BRAF and renal cell carcinoma: Previous studies have demonstrated that the MET-overexpressing RCC PDX harbors activating BRAF (G466A and D594N) mutations and is sensitive to both MET (INC280, or capmatinib) and MEK (trametinib) inhibition.